Mounjaro could help reduce the risk of developing breast cancer tumors has suggested exciting new research.
The game-changing weight loss Jabs have ushered in a new era in the war against obesity, but are also linked to other health benefits, such as reducing the risk of heart attacks, strokes and kidney diseases.
Now scientists have discovered that Tirzepatide – the ingredient behind Mounjaro – considerably delays the growth of breast cancer tumors.
American scientists, who carried out the process, said the findings about mice show that the medicines have a ‘favorable impact’ on women with the disease.
However, they warned that further research was needed to confirm their findings.
Nor did researchers speculate why the medicine, which belongs to the class of medicines called GLP-1 agonists, could lower the chances of a patient’s cancer.
It comes as a breakthrough examination in May that GLP-1’s could help to help up to 14 types of cancer, including chest.
Studies have also suggested that obesity is an important risk factor when returning breast cancer and weight loss could improve the results.
The game-changing weight loss Jabs have initated a new era in the war against obesity, but are also linked to other health benefits, such as reducing the risk of heart attacks, terrores and kidney disease
Amanda Kucinskas, a researcher in obesity and breast cancer risk at the University of Michigan and studies the author, said: ‘Although they are very provisional data, our studies in mice suggest that these new anti-obesity drugs can be a way to reduce the risk of obesity-associated breast cancer or to improve the results.
“Although these are very provisional results, they suggest that this new anti-annoying medicine can also have a favorable impact on the results of breast cancer,” “
In the study, researchers followed 16 nine -week -old mice with breast cancer tumors who received a high -fat diet to cause obesity.
At 32 weeks old – roughly middle -aged for a mouse – the obese animals were divided into two groups.
One group received tirzepatide injections and the other a placebo for the next for 16 weeks.
Scientists then measure the weight of the mice and tumor growth twice a week.
They found mice about the drug lost around one fifth of their body weight – the average weight lost by patients who took Mounjaro in the long term.
The fat loss mainly took place in fatty tissue, the fat storage cells of the body.
Currently, all women between the ages of 50 and 70 are invited for screening every three years, with the first invitation between the ages of 50 and 53
Mice treated with tirzepatide also had considerably smaller tumors, the scientists said.
There was a ‘clear link’ between the lower body weight and the smaller tumor size, while the total fat mass was also ‘strongly connected’ to how large the tumors became, they added.
However, they warned that exactly how tirzepatide tumor growth was delayed, was not yet understood and further tests, even in people, would first be needed.
The findings were fully presented this week Endo 2025, the annual meeting of the Endocrine Society in San Francisco.
It is presented as a research at the annual conference of the American Society for Clinical Oncology (ASCO) in May suggested that GLP-1S can beat the risk of 14 obesity-related cancer-inclusive breast-zou for people with diabetes.
American scientists discovered that on GLP-1’s had a 7 percent lower risk of developing an obesity-related cancer than patients with DDP-4 inhibitors, a different diabetes medication.
When other health benefits were processed, these patients were also 8 percent less likely to die during the 10 -year period.
In December, groundbreaking research presented at the San Antonio Breast Cancer Symposium also suggested The Jabs can also help protect against breast cancer return.
One study of more than 1,000 patients by the University of Texas found obese patients who took the drugs just over a year after completing the treatment on average a ‘considerably improved’ chance of living longer.
Surprisingly, however, they also found that patients used hormone medicines, such as tamoxifen – for many women to stop repeating breast cancer – weight, despite the use of the Jabs.
At the time, experts MailOnline told them that they were not sure why this happened.
But they suggested that it can be because hormone therapy usually ensures that patients arrive, which means that the Jabs cannot work effectively.
For these patients, “we may have to go to a higher dose,” said Professor Neil Iyengar, then an oncologist at the Memorial Sloan Kettering Cancer Center, New York.
#Scientists #discover #link #Mounjaro #breast #cancer